Shares of Gain Therapeutics, Inc. (NASDAQ:GANX – Get Rating) rose 0.8% during trading on Thursday . The company traded as high as $3.95 and last traded at $3.90. Approximately 17,025 shares were traded during trading, a decline of 81% from the average daily volume of 90,065 shares. The stock had previously closed at $3.87.
Analyst Ratings Changes
Separately, B. Riley lowered Gain Therapeutics from a “buy” rating to a “neutral” rating and cut their price target for the company from $11.00 to $5.00 in a research note on Friday, August 19th.
Gain Therapeutics Stock Up 0.8 %
The company has a quick ratio of 7.58, a current ratio of 7.58 and a debt-to-equity ratio of 0.02. The stock has a 50 day simple moving average of $3.85 and a 200 day simple moving average of $3.65. The stock has a market cap of $46.34 million, a price-to-earnings ratio of -2.89 and a beta of 0.07.
Institutional Inflows and Outflows
About Gain Therapeutics
Gain Therapeutics, Inc, a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease.
- Get a free copy of the StockNews.com research report on Gain Therapeutics (GANX)
- No One Told These 3 Stocks It’s a Down Week
- Is There a Cure for What is Ailing Teladoc Stock?
- Why Medical Products Maker Repligen May Be A Potential Buy
- At 10%, Is Arbor Realty Trust Dividend Worth It?
- Investors Should Tune Into RF Industries
Receive News & Ratings for Gain Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gain Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.